Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.

Christian Laugesen Ajenthen Gayathri Ranjan Signe Schmidt Kirsten Nørgaard

Published in: Diabetologia (2023)

ClinicalTrials.gov NCT04764968 FUNDING: The study was an investigator-initiated trial. Zealand Pharma supplied the investigational drug and device and provided financial support for the conduct of the trial.

Keyphrases

phase ii
open label
phase iii
clinical trial
study protocol
placebo controlled
phase ii study
double blind
low dose
healthcare
type diabetes
palliative care
high dose
randomized controlled trial
quality improvement
squamous cell carcinoma
pain management
emergency department